Contents

Disclaimer

Oxford University Press makes no representation, express or implied, that the drug dosages in this book are correct. Readers must therefore always check the product information and clinical procedures with the most up to date published product information and data sheets provided by the manufacturers and the most recent codes of conduct and safety regulations. The authors and the publishers do not accept responsibility or legal liability for any errors in the text or for the misuse or misapplication of material in this work. Except where otherwise stated, drug dosages and recommendations are for the non-pregnant adult who is not breastfeeding.

Show Summary Details
Page of

The Abbott HeartMate 3™ Left Ventricular Assist System 

The Abbott HeartMate 3™ Left Ventricular Assist System
Chapter:
The Abbott HeartMate 3™ Left Ventricular Assist System
Author(s):

Kevin Bourque

and John B. O’Connell

DOI:
10.1093/med/9780190909291.003.0012
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 18 January 2021

Mechanical circulatory support devices are increasingly used to treat chronic, advanced heart failure. In the Abbott HeartMate 3™ left ventricular assist system (HM3), a new magnetic levitation pump improves hemocompatibility and thus addresses the prominent morbidities associated with these devices, such as pump thrombosis, stroke, and bleeding. In the multicenter MOMENTUM 3 clinical trial of 366 patients, the primary endpoint—survival without disabling stroke or pump replacement—was 77.9% in the HM3 group (n = 190) and 56.4% in the HeartMate II™ Left Ventricular Assist System group (HMII; n = 176; P <0.001). Suspected or confirmed pump thrombosis occurred in two patients (1.1%) in the HM3 group and in 27 patients (15.7%) in the HMII group (P <0.001). Also at 2 years, 22 strokes occurred in 19 patients (10.1%) with the HM3 and 43 strokes occurred in 33 patients (19.2%) with the HMII (P = 0.02), indicating that the HM3 provides important improvements in care.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.